9 results on '"Doi, Takahito"'
Search Results
2. Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial.
- Author
-
Doi, Takahito, Langsted, Anne, and Nordestgaard, Børge G.
- Subjects
- *
LDL cholesterol , *CHOLESTEROL , *APOLIPOPROTEIN B , *MYOCARDIAL infarction , *LIPOPROTEINS - Abstract
The PROMINENT trial, a cardiovascular outcome trial of the triglyceride- and remnant cholesterol-lowering agent pemafibrate, has shown neutral results despite reduction in plasma triglycerides and remnant cholesterol. We tested the hypothesis that absolute mass changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B explain the results of the PROMINENT trial. Among 108,431 individuals from the Copenhagen General Population Study (CGPS), those who met the key inclusion criteria of the PROMINENT trial were analyzed to mimic the trial design. Endpoint atherosclerotic cardiovascular disease (ASCVD) was cardiovascular death, myocardial infarction, ischemic stroke, and coronary revascularization as defined in PROMINENT. In the PROMINENT trial, treatment with pemafibrate resulted in -7 mg/dL (−0.18 mmol/L; -18 %) change in remnant cholesterol, +10 mg/dL (+0.26 mmol/L; +12 %) LDL cholesterol, and +5 mg/dL (+0.05 g/L; +5 %) apolipoprotein B. In the CGPS mimicking PROMINENT, the estimated hazard ratios for ASCVD were 0.97 (95 % confidence interval: 0.94–0.99) for a -7 mg/dL (−0.18 mmol/L) change in remnant cholesterol, 1.04 (1.01–1.07) for a +10 mg/dL (+0.26 mmol/L) change in LDL cholesterol, and 1.02 (1.01–1.03) for a +5 mg/dL (+0.05 g/L) change in apolipoprotein B. When combining absolute changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B, the estimated hazard ratio for ASCVD was 1.05 (0.96–1.14) in the CGPS mimicking PROMINENT compared to 1.03 (0.91–1.15) in the PROMINENT trial. Absolute mass changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B can explain results of the PROMINENT trial. The 3 mg/dL (0.08 mmol/L) higher total atherogenic cholesterol together with 5 mg/dL (0.05 g/L) higher apolipoprotein B seem to explain the trend toward more ASCVD in the pemafibrate arm. [Display omitted] • Absolute mass changes in remnant cholesterol, LDL cholesterol, and apo B can explain results of the PROMINENT trial. • To reduce ASCVD lipid lowering drugs, total atherogenic cholesterol and total number of atherogenic particles need to be reduced. • Understanding the potential for causing ASCVD, lipoproteins should be judged by their absolute mass of cholesterol content. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction.
- Author
-
Doi, Takahito, Langsted, Anne, and Nordestgaard, Børge G.
- Subjects
- *
CORONARY disease , *MYOCARDIAL ischemia , *MYOCARDIAL infarction , *CARDIOMYOPATHIES , *CHOLESTEROL , *TRIGLYCERIDES , *ANTILIPEMIC agents , *HYPERCHOLESTEREMIA , *DISEASE complications - Abstract
Background: Elevated remnant cholesterol causes ischemic heart disease.Objectives: We tested the hypothesis that the inclusion of elevated remnant cholesterol will lead to appropriate reclassification of individuals who later experience myocardial infarction and ischemic heart disease.Methods: For >10 years we followed up 41,928 white Danish individuals from the Copenhagen General Population Study without a history of ischemic cardiovascular disease, diabetes, and statin use. Using predefined cut points for elevated remnant cholesterol, we calculated net reclassification index (NRI) from below to above 5%, 7.5%, and/or 10% 10-year occurrence of myocardial infarction and ischemic heart disease defined as a composite of death from ischemic heart disease, myocardial infarction, and coronary revascularization.Results: For individuals with remnant cholesterol levels ≥95th percentile (≥1.6 mmol/L, 61 mg/dL), 23% (P < 0.001) of myocardial infarction and 21% (P < 0.001) of ischemic heart disease were reclassified correctly from below to above 5% for 10-year occurrence when remnant cholesterol levels were added to models based on conventional risk factors, whereas no events were reclassified incorrectly. Consequently, the addition of remnant cholesterol levels yielded NRI of 10% (95% CI: 1%-20%) for myocardial infarction and 5% (95% CI: -3% to 13%) for ischemic heart disease. Correspondingly, when reclassifications were combined from below to above 5%, 7.5%, and 10% risk of events, 42% (P < 0.001) of individuals with myocardial infarction and 41% (P < 0.001) with ischemic heart disease were reclassified appropriately, leading to NRI of respectively 20% (95% CI: 9%-31%) and 11% (95% CI: 2%-21%).Conclusions: Elevated remnant cholesterol levels considerably improve myocardial infarction and ischemic heart disease risk prediction. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.
- Author
-
Doi, Takahito, Langsted, Anne, and Nordestgaard, Børge G.
- Subjects
- *
C-reactive protein , *MYOCARDIAL infarction , *CARDIOVASCULAR diseases , *CHOLESTEROL , *MORTALITY - Abstract
Elevated remnant cholesterol and low-grade inflammation each cause atherosclerotic cardiovascular disease (ASCVD); however, it is unknown whether joint elevation of both factors confers the highest risk. We tested the hypothesis that dual elevated remnant cholesterol and low-grade inflammation marked by elevated C-reactive protein is associated with the highest risk of myocardial infarction, ASCVD, and all-cause mortality. The Copenhagen General Population Study randomly recruited white Danish individuals aged 20–100 years in 2003–2015 and followed them for a median 9.5 years. ASCVD was cardiovascular mortality, myocardial infarction, stroke, and coronary revascularization. In 103,221 individuals, we observed 2,454 (2.4%) myocardial infarctions, 5,437 (5.3%) ASCVD events, and 10,521 (10.2%) deaths. The hazard ratios increased with each of stepwise higher remnant cholesterol and stepwise higher C-reactive protein. In individuals with the highest tertile of both remnant cholesterol and C-reactive protein compared to individuals with the lowest tertile of both, the multivariable adjusted hazard ratios were 2.2 (95%CI:1.9–2.7) for myocardial infarction, 1.9 (1.7–2.2) for ASCVD, and 1.4 (1.3–1.5) for all-cause mortality. Corresponding values for only the highest tertile of remnant cholesterol were 1.6 (1.5–1.8), 1.4 (1.3–1.5), and 1.1 (1.0–1.1), and those for only the highest tertile of C-reactive protein were 1.7 (1.5–1.8), 1.6 (1.5–1.7), and 1.3 (1.3–1.4), respectively. There was no statistical evidence for interaction between elevated remnant cholesterol and elevated C-reactive protein on risk of myocardial infarction (p = 0.10), ASCVD (p = 0.40), or all-cause mortality (p = 0.74). Dual elevated remnant cholesterol and C-reactive protein confers the highest risk of myocardial infarction, ASCVD, and all-cause mortality, that is, compared to either of these two factors individually. [Display omitted] • Dual elevated remnant-C and CRP was associated with the highest risk of ASCVD. • ASCVD risk is particularly relevant if remnant-C is ≥ 0.8 mmol/L and CRP ≥1.5 mg/L. • ASCVD risk was double in the highest tertile of both compared to the lowest. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Coronary artery ectasia: Importance of its risk stratification and management.
- Author
-
Kataoka, Yu and Doi, Takahito
- Subjects
- *
CORONARY arteries , *ABDOMINAL aortic aneurysms , *MYOCARDIAL infarction , *CORONARY artery stenosis - Published
- 2021
- Full Text
- View/download PDF
6. Combined evaluation of plasma B-type natriuretic peptide and urinary liver-type fatty acid-binding protein/creatinine ratio is related to worsening renal function in patients undergoing elective percutaneous coronary intervention.
- Author
-
Yoshihara, Fumiki, Hosoda, Hiroshi, Doi, Takahito, Yoshida, Morikatsu, Kitamura, Kazuo, Yamamoto, Haruko, Asaumi, Yasuhide, Ishibashi-Ueda, Hatsue, Kishida, Masatsugu, Arisato, Tetsuya, Matsuo, Miki, Miyazato, Mikiya, and Yasuda, Satoshi
- Subjects
- *
FATTY acid-binding proteins , *PERCUTANEOUS coronary intervention , *KIDNEY physiology , *PRASUGREL , *BRAIN natriuretic factor , *KIDNEY tubules , *CORONARY angiography , *PROTON magnetic resonance spectroscopy - Abstract
Background: There are few reports on the significance for the combined evaluation of blood humoral factors and urinary biomarkers in terms of worsening renal function (WRF) after coronary angiography (CAG)/percutaneous coronary arterial intervention (PCI). Method and results: Urinary liver type-fatty acid-binding protein (L-FABP), neutrophil gelatinase associated lipocalin (NGAL), and adrenomedullin (AM) were measured less than 24 h before and 3 h, 6 h, 1 day, and 2 days after CAG/PCI. WRF was defined as a > 20% decrease in the estimated GFR. WRF occurred in seven of 100 patients and the increase in L-FABP/creatinine (Cr) at 1 day after CAG/PCI was significantly higher in the WRF group than in the non-WRF group. Plasma B-type natriuretic peptide (BNP) before CAG/PCI and L-FABP/Cr at 1 day after CAG/PCI were independent predictors for WRF. The areas under the receiver-operating characteristic curves were as follows: 0.760 for BNP before CAG/PCI, 0.731 for L-FABP/Cr at 1 day after CAG/PCI, and 0.892 for BNP and L-FABP/Cr. Urinary AM levels after PCI/CAG were negatively correlated only to serum potassium levels. Gene expressions of AM and AM-receptor were detectable in renal tubule epithelial cells. AM increased intracellular second messenger levels in a dose-dependent manner. Conclusions: Our results suggest that combined evaluation of plasma BNP and urinary L-FABP/Cr is useful as a predictor of renal dysfunction in CAG/PCI patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Abstract 11157: Prevalence, Clinical Characteristics and Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia Patients With Double-Heterozygous Mutation of LDLR and PCSK9 Gain-Of-Function Mutation.
- Author
-
Doi, Takahito, Hori, Mika, Harada-Shiba, Mariko, Kataoka, Yu, Nishikawa, Ryo, Tsuda, Kosuke, Nishimura, Kunihiro, Ogura, Masatsune, Noguchi, Teruo, and Yasuda, Satoshi
- Subjects
- *
GAIN-of-function mutations , *HYPERCHOLESTEREMIA , *LIPOPROTEIN receptors , *CARDIAC patients , *SUBTILISINS , *HETEROZYGOUS familial hypercholesterolemia - Abstract
Introduction: Low-density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) have been recognized as causative genes of heterozygous familial hypercholesterolemia (HeFH) which exhibited a marked elevation of LDL-C and premature atherosclerotic cardiovascular disease (ASCVD). Recent study reported the presence of both mutations was infrequently observed in HeFH subjects. It remains to be fully elucidated whether this double-heterozygous mutation in LDLR and PCSK9 gene (LDLR/PCSK9) affects clinical demographics and cardiac outcome in HeFH patients. Methods: 377 clinically diagnosed HeFH probands were retrospectively analyzed. Clinical characteristics and the occurrence of MACE were compared among subjects stratified according to genotypes (LDLR/PCSK9 career, LDLR alone, and PCSK9 alone). Results: The frequency of probands with LDLR/PCSK9 , LDLR and PCSK9 gain-of-function mutation was 4, 48 and 9%, respectively. Probands with LDLR/PCSK9 were more likely to exhibit a higher LDL-C level at baseline (Table) and receive high-intensity statin (43, 16 and 6%, respectively, p=0.01 for trend). During follow-up period, probands with LDLR/PCSK9 demonstrated a lower on-treatment LDL-C level (p=0.02) and its greater percent reduction were observed under lipid-lowering therapy, although the latter comparison did not meet statistical significance (Table, p=0.08). However, probands with LDLR/PCSK9 were associated with 3.0 and 8.2-fold likelihood of experiencing cardiovascular events compared to LDLR and PCSK9 , respectively (Figure). Even after adjusting covariates, the presence of LDLR/PCSK9 was still an independent predictor for MACE (p=0.01 vs. LDLR ; p=0.007 vs. PCSK9). Conclusions: The presence of double-heterozygous mutation in the LDLR and PCSK9 gene predicted cardiac events in patients with HeFH. These findings underscore precise medicine to identify patients with double-heterozygous mutation who require more stringent management. [ABSTRACT FROM AUTHOR]
- Published
- 2018
8. The feasibility and limitation of coronary computed tomographic angiography imaging to identify coronary lipid-rich atheroma in vivo: Findings from near-infrared spectroscopy analysis.
- Author
-
Kitahara, Satoshi, Kataoka, Yu, Miura, Hiroyuki, Nishii, Tatsuya, Nishimura, Kunihiro, Murai, Kota, Iwai, Takamasa, Nakamura, Hayato, Hosoda, Hayato, Matama, Hideo, Doi, Takahito, Nakashima, Takahiro, Honda, Satoshi, Fujino, Masashi, Nakao, Kazuhiro, Yoneda, Shuichi, Nishihira, Kensaku, Kanaya, Tomoaki, Otsuka, Fumiyuki, and Asaumi, Yasuhide
- Subjects
- *
TOMOGRAPHY , *NEAR infrared spectroscopy , *COMPUTED tomography , *RECEIVER operating characteristic curves , *ATHEROSCLEROTIC plaque - Abstract
Coronary computed tomography angiography (CCTA) non-invasively visualizes lipid-rich plaque. However, this ability is not fully validated in vivo. The current study aimed to elucidate the association of CCTA features with near-infrared spectroscopy-derived lipidic plaque measure in patients with coronary artery disease. 95 coronary lesions (culprit/non-culprit = 51/44) in 35 CAD subjects were evaluated by CCTA and NIRS imaging. CT density, positive remodeling, spotty calcification, napkin-ring sign and NIRS-derived maximum 4-mm lipid-core burden index (maxLCBI 4mm) were analyzed by two independent physicians. The association of CCTA-derived plaque features with maxLCBI 4mm ≥ 400 was evaluated. The median CT density and maxLCBI 4mm were 57.7 Hounsfield units (HU) and 304, respectively. CT density (r = -0.75, p < 0.001) and remodeling index (RI) (r = 0.58, p < 0.001) were significantly associated with maxLCBI 4mm , respectively. Although napkin-ring sign (p < 0.001) showed higher prevalence of maxLCBI 4mm ≥ 400 than those without it, spotty calcification did not (p = 0.13). On multivariable analysis, CT density [odds ratio (OR) = 0.95, 95% confidence interval (CI) = 0.93–0.97; p < 0.001] and positive remodeling [OR = 7.71, 95%CI = 1.37–43.41, p = 0.02] independently predicted maxLCBI 4mm ≥ 400. Receiver operating characteristic curve analysis demonstrated CT density <32.9 HU (AUC = 0.92, sensitivity = 85.7%, specificity = 91.7%) and RI ≥ 1.08 (AUC = 0.83, sensitivity = 74.3%, specificity = 85.0%) as optimal cut-off values of maxLCBI 4mm ≥ 400. Of note, only 52.6% at lesions with one of these plaque features exhibited maxLCBI 4mm ≥ 400, whereas the frequency of maxLCBI 4mm ≥ 400 was highest at those with both features (88.5%, p < 0.001 for trend). CT density <32.9 HU and RI ≥ 1.08 were associated with lipid-rich plaque on NIRS imaging. Our findings underscore the synergistic value of CT density and positive remodeling to detect lipid-rich plaque by CCTA. [Display omitted] • Positive remodeling and low CT density independently associated with near-infrared spectroscopy-derived lipidic measure. • CT density and positive remodeling were independent predictors of lipid-rich plaque. • CT density <32.9 HU and remodeling index ≥1.08 were optimal cut-off values of lipid-rich plaque. • CT density and positive remodeling have synergistic value to detect lipid-rich plaque by coronary CT angiography. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Cardiac outcomes in patients with acute coronary syndrome attributable to calcified nodule.
- Author
-
Sugane, Hiroki, Kataoka, Yu, Otsuka, Fumiyuki, Nakaoku, Yuriko, Nishimura, Kunihiro, Nakano, Hiroki, Murai, Kota, Honda, Satoshi, Hosoda, Hayato, Matama, Hideo, Doi, Takahito, Nakashima, Takahiro, Fujino, Masashi, Nakao, Kazuhiro, Yoneda, Shuichi, Tahara, Yoshio, Asaumi, Yasuhide, Noguchi, Teruo, Kawai, Kazuya, and Yasuda, Satoshi
- Subjects
- *
ACUTE coronary syndrome , *CARDIAC patients , *INTRAVASCULAR ultrasonography , *PROPORTIONAL hazards models , *PERCUTANEOUS coronary intervention , *KIDNEY calcification - Abstract
Calcified nodule (CN) is an eruptive calcified mass causing acute coronary syndrome (ACS). Since coronary calcification is associated with an elevated cardiac event's risk, ACS attributable to CN may exhibit worse clinical outcome following percutaneous coronary intervention (PCI). We retrospectively analyzed 657 ACS patients receiving PCI with newer-generation drug-eluting stent (DES) implantation under intravascular ultrasound (IVUS) guidance. CN was defined as (1) protruding calcification with its irregular surface and (2) the presence of calcification at adjacent proximal and distal segments. The primary endpoint was a composite of major adverse cardiac event [MACE = cardiac death + ACS recurrence + target lesion revascularization (TLR)]. CN was identified in 5.3% (=35/657) of the study subjects. CN patients were more likely to have coronary risk factors including hypertension (p = 0.005), chronic kidney disease (p < 0.001), maintenance hemodialysis (p < 0.001) and a history of PCI (p < 0.001). During the observational period (median = 1304 days), CN was associated with an increased risk of MACE (HR = 7.68, 95%CI = 4.61–12.80, p < 0.001), ACS recurrence (HR = 12.32, 95%CI = 6.05–25.11, p < 0.001) and TLR (HR = 10.48, 95%CI = 5.80–18.94, p < 0.001). These cardiac risks related to CN were consistently observed by Cox proportional hazards model (MACE: p < 0.001, ACS recurrence: p < 0.001, TLR: p < 0.001) and a propensity score–matched cohort analysis (MACE: p = 0.002, ACS recurrence: p = 0.01, TLR: p = 0.005). Of note, over 80% of TLR at the CN lesion was driven by its re-appearance within the implanted DES. ACS patients attributable to CN have an increased risk of ACS recurrence and TLR, mainly driven by the continuous growth and protrusion of the calcified mass. Image 1 • Acute coronary syndrome (ACS) patients attributable to calcified nodule (CN) exhibited significant heightened risk of adverse cardiac events compared to those without. • In ACS patients attributable to calcified nodule, recurrence of ACS occurred mainly due to in-stent restenosis. • Over 80% of in-stent restenosis at lesions containing CN exhibited its re-appearance within the implanted stent.. • Our findings suggest the need for additional therapeutic approach to modify CN in ACS subjects.. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.